Fig. 11

Verified the predictive efficacy of the risk score based on the data from the IMvigor210 cohort. A Correlation map of response (complete response / partial response) and nonresponse (stable disease / progressive disease) to immunotherapy in different risk score groups. B Relative percent of response and nonresponse to immunotherapy in the Risk-H and Risk-L groups. C Comparison of the difference between response and nonresponse groups. D Kaplan–Meier curves of overall survival time of the high- and low-risk score groups in the metastatic urothelial carcinoma (mUC) sample. E The survival ROC curves of risk score in the mUC sample